Blog
Federal Circuit Clarifies Limits of Interference Estoppel in Patent Reviews: IGT v. Zynga
July 22, 2025
IGT v. Zynga Inc Authored by: Jeremy J. Gustrowsky In a significant decision for patent litigation and the gaming industry, the Federal Circuit affirmed the unpatentability of several claims in IGT’s U.S. Patent No. 7,168,089, which covers secure software transfers…
Read MorePatent Infringement Win Overturned: Colibri Heart Valve Loses $106 Million Verdict Against Medtronic
July 18, 2025
Colibri Heart Valve LLC v. Medtronic Corevalve, LLC Authored by: Jeremy J. Gustrowsky In a significant patent law decision, the Federal Circuit reversed a $106 million jury verdict in favor of Colibri Heart Valve LLC against Medtronic CoreValve, LLC, ruling…
Read MoreUnderstanding Your Company’s Intellectual Property Assets
July 16, 2025
What makes up your company’s intellectual property assets? At the core of every business lies proprietary information, which often serves as a crucial competitive advantage. This can encompass a wide range of items, such as customer data, product designs, strategic…
Read MoreFederal Circuit Clarifies Use of Applicant Admitted Prior Art in Patent Challenges
July 14, 2025
Shockwave Med., Inc. v. Cardiovascular Sys Authored by: Jeremy J. Gustrowsky In the recent case of Shockwave Medical, Inc. v. Cardiovascular Systems, Inc., the Federal Circuit addressed how “Applicant Admitted Prior Art” (AAPA) can be used in patent challenges before…
Read MorePatent Board Denies Rehearing for DeepMind’s Machine Learning Patent Application
July 14, 2025
USPTO Authored by: Jeremy J. Gustrowsky In a recent decision, the Patent Trial and Appeal Board (PTAB) denied a request for rehearing from DeepMind Technologies Limited regarding their U.S. Patent Application No. 16/319,040. The application, which focuses on improving machine…
Read MoreFederal Circuit Upholds Janssen’s Invega Sustenna Patent Against Obviousness Challenge
July 8, 2025
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc Authored by: Jeremy J. Gustrowsky In a significant decision for pharmaceutical patent holders, the Federal Circuit has affirmed the validity of Janssen Pharmaceuticals’ U.S. Patent No. 9,439,906, which covers specific dosing regimens…
Read MoreFederal Circuit Clarifies Obviousness Standards for Drug Dosing Patents
July 8, 2025
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit provided important guidance on how courts should analyze the obviousness of pharmaceutical dosing regimen patents. The case involved Janssen’s U.S.…
Read MoreFederal Circuit Affirms Cisco’s Win Over Egenera in Virtual Network Patent Dispute
July 7, 2025
Egenera, Inc. v. Cisco Sys., Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit upheld a district court’s ruling that Cisco Systems, Inc. did not infringe Egenera, Inc.’s U.S. Patent No. 7,231,430, which covers technology for…
Read MoreFederal Circuit Narrows “Consisting Essentially Of” in Eye Therapies v. Slayback Pharma Patent Dispute
June 30, 2025
Eye Therapies, LLC v. Slayback Pharma, LLC Authored by: Jeremy J. Gustrowsky In a significant decision for patent claim interpretation, the Federal Circuit recently reversed a Patent Trial and Appeal Board (PTAB) ruling in Eye Therapies, LLC v. Slayback Pharma,…
Read MoreFederal Circuit Dismisses Realtek’s Appeal Over ITC Sanctions for Lack of Jurisdiction
June 18, 2025
Realtek Semiconductor Corp. v. Int’l Trade Comm’n Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit clarified the limits of its authority to review certain decisions made by the U.S. International Trade Commission (ITC). The case, Realtek…
Read MoreProtect Your Brand: Unlock the Power of Your Intellectual Property
June 18, 2025
As a business owner, it’s essential to recognize what makes your brand unique—this includes identifying your intellectual property (IP) assets. From words and logos to colors, sounds, and even packaging, anything that sets your products and services apart from the…
Read MoreFederal Circuit Vacates PTAB Ruling on Software Patent, Citing Flawed Review of Licensing Deals
June 16, 2025
Ancora Techs., Inc. v. Roku, Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the U.S. Court of Appeals for the Federal Circuit stepped into a patent dispute over technology designed to protect licensed software from unauthorized copying on…
Read More